Elizabeth J. Kelly

AstraZeneca (Finland) — Finland

Medicine · Health Sciences

35h-index14.9kcitations91works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(40), COVID-19 Clinical Research Studies(24), Respiratory viral infections research(16), Virus-based gene therapy research(12), Animal Virus Infections Studies(10)

Publications82 total

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab
The Pediatric Infectious Disease Journal·2026Open Access
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial
Journal of Infection·2025Open Access
A Pragmatic Approach to Improving Management and Patient Flow for Painful Diabetic Neuropathy in UK Primary Care
Diabetes Therapy·2025Open Access
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Mayo Clinic Proceedings Innovations Quality & Outcomes·2025Open Access
P-2179. Nirsevimab in Patient Samples Does Not Interfere with Respiratory Syncytial Virus (RSV) Detection by Commercially Available Rapid Antigen Tests
Open Forum Infectious Diseases·2025Open Access
Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)
Clinical Infectious Diseases·2024· 11 citedOpen Access
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
PEDIATRICS·2024· 26 citedOpen Access
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
Vaccine·2024· 3 citedOpen Access
Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study
Vaccines·2024· 2 citedOpen Access
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
The Lancet Microbe·2024· 6 citedOpen Access
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity
Frontiers in Immunology·2024· 2 citedOpen Access
The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus
Nature Communications·2024· 21 citedOpen Access
Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Nature Communications·2024· 2 citedOpen Access
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
Human Vaccines & Immunotherapeutics·2024· 2 citedOpen Access
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12
Molecular Therapy Oncology·2024· 7 citedOpen Access
2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
Open Forum Infectious Diseases·2023· 3 citedOpen Access
1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
Open Forum Infectious Diseases·2023Open Access
1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
Open Forum Infectious Diseases·2023· 2 citedOpen Access
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
Infectious Diseases and Therapy·2023· 3 citedOpen Access
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
Frontiers in Immunology·2023· 28 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Tonya Villafana(13), Deidre Wilkins(10), Teresa Lambe(8), Anastasia A. Aksyuk(8), Andrew J. Pollard(7), Kathryn Shoemaker(7), Kevin M. Tuffy(7), Parvinder K. Aley(6), Nicholas M. Durham(6), Sagida Bibi(6), Stephen J. Russell(6), Michael E. Abram(6), Brett Jepson(5), Johan Vekemans(5), Mark T. Esser(5), Ann R. Falsey(5), Magdalena E. Sobieszczyk(5), Shabir A. Madhi(4), Merryn Voysey(4), Sarah C. Gilbert(4)